



High Frequency Chest Wall Oscillation

Origination: 12/16/09	Revised: 12/18/23	Annual Review: 11/12/24
Line of Business: Commercial Only <input type="checkbox"/> QHP/Exchange Only <input type="checkbox"/> Medicare Only <input type="checkbox"/> Commercial & QHP/Exchange <input checked="" type="checkbox"/> Commercial, QHP/Exchange, & Medicare <input type="checkbox"/>		

Purpose:

To provide high frequency chest wall oscillation guidelines for Population Health and Provider Alliances associates to reference when making benefit determinations.

Coverage Guidelines

High Frequency Chest wall oscillation is only considered indicated for Cystic Fibrosis or Bronchiectasis or one (1) of the following neuromuscular disease diagnoses:

- Post-polio.
- Acid maltase deficiency.
- Anterior horn cell diseases.
- Multiple sclerosis.
- Quadriplegia.
- Hereditary muscular dystrophy.
- Myotonic disorders.
- Other myopathies.
- Paralysis of the diaphragm with documented failure to adequately mobilize secretions.

Exclusion Criteria

- High frequency chest wall oscillation devices are considered investigational.
- It is not indicated for COPD/Chronic Bronchitis.

Disclaimer Information:

Coverage Issues Guidelines and Medical Technology Assessment Recommendations are developed to determine coverage for AvMed’s benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. AvMed makes coverage decisions using these guidelines, along with the Member's benefit document. The use of this guideline is neither a guarantee of payment nor a final prediction of how specific claim(s) will be adjudicated.

Coverage Issues Guidelines and Medical Technology Assessment Recommendations are developed for selected therapeutic or diagnostic services found to be safe, but proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the AvMed service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations.

Treating providers are solely responsible for the medical advice and treatment of Members. This guideline may be updated and therefore is subject to change.